Citadel Advisors
MXCT icon

Citadel Advisors’s MaxCyte MXCT Stock Holding History

Citadel Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,000
Closed -$25K – 15210
2024
Q4 		$25K Buy
6,000
+4,000
+200% +$15.1K ﹤0.01% 13032
2024
Q3 		$7.78K Sell
2,000
-700
-26% -$2.95K ﹤0.01% 13342
2024
Q2 		$10.6K Buy
2,700
+600
+29% +$2.58K ﹤0.01% 13078
2024
Q1 		$8.8K Sell
2,100
-600
-22% -$2.82K ﹤0.01% 13532
2023
Q4 		$12.7K Sell
2,700
-6,600
-71% -$25.7K ﹤0.01% 12977
2023
Q3 		$29K Buy
9,300
+5,300
+133% +$21.3K ﹤0.01% 12297
2023
Q2 		$18.4K Buy
4,000
+1,400
+54% +$6.43K ﹤0.01% 12802
2023
Q1 		$12.9K Buy
2,600
+1,900
+271% +$9.36K ﹤0.01% 13383
2022
Q4 		$3.82K Buy
+700
New +$4.29K ﹤0.01% 14168

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Citadel Advisors's MXCT Position: Q1 2026 in Review

Citadel Advisors reduced its MaxCyte (MXCT) stake by 78% in Q1 2026, selling an estimated $1.08M and leaving 333,088 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #11068.

Citadel Advisors first reported a position in MXCT in Q4 2021 and has held it in 18 quarters since. The position peaked at $11.6M in Q4 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Citadel Advisors held 333,088 shares of MaxCyte worth $234K as of Q1 2026.
  • Citadel Advisors sold 1,155,730 MaxCyte shares in Q1 2026, an estimated $1.08M.
  • MaxCyte made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11068 holding.
  • Citadel Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 18 quarters since.
  • Citadel Advisors's MaxCyte position peaked at $11.6M in Q4 2022.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.